| [1] |
许骏,王本忠.乳腺癌内分泌治疗[J/CD].中华乳腺病杂志:电子版,2008,2(3):324-330.
|
| [2] |
Jemal A, Siegel R, Xu J, et al.Cancer statistics, 2010[J].CA Cancer J Clin,2010,60(5):277-300.
|
| [3] |
Karn A, Jha AK, Shrestha S, et al.Tamoxifen for breast cancer[J].JNMA J Nepal Med Assoc,2010,49(177):62-67.
|
| [4] |
Yu KD, Shao ZM.Genetic matters of CYP2D6 in breast cancer: copy number variations and nucleotide polymorphisms[J].Nat Rev Cancer,2009,9(11):842.
|
| [5] |
Hoskins JM, Carey LA, Mcleod HL.CYP2D6 and tamoxifen: DNA matters in breast cancer[J].Nat Rev Cancer,2009,9(8):576-586.
|
| [6] |
Zhou SF.Polymorphism of human cytochrome P450 2D6 and its clinical significance: part Ⅱ[J].Clin Pharmacokinet,2009,48(12):761-804.
|
| [7] |
Higgins MJ, Rae JM, Flockhart DA, et al.Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing[J]? J Natl Compr Canc Netw,2009,7(2):203-213.
|
| [8] |
Coate L, Cuffe S, Horgan A, et al.Germline genetic variation, cancer outcome, and pharmacogenetics[J].J Clin Oncol,2010,28(26):4029-4037.
|
| [9] |
Seruga B, Amir E.Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis[J].Breast Cancer Res Treat,2010,122(3):609-617.
|
| [10] |
Bradford LD.CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants [J].Pharmacogenomics,2002,3(2):229-243.
|
| [11] |
Jin Y, Desta Z, Stearns V, et al.CYP2D6 genotype, antide-pressant use, and tamoxifen metabolism during adjuvant breast cancer treatment[J].J Natl Cancer Inst,2005,97(1):30-39.
|
| [12] |
Lim HS, Ju LH, Seok LK, et al.Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer[J].J Clin Oncol,2007,25(25):3837-3845.
|
| [13] |
Thompson AM, Johnson A, Quinlan P, et al.Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy[J].Breast Cancer Res Treat,2011,125(1):279-287.
|
| [14] |
Goetz MP, Rae JM, Suman VJ, et al.Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes[J].J Clin Oncol,2005,23(36):9312-9318.
|
| [15] |
Goetz MP, Knox SK, Suman VJ, et al.The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen[J].Breast Cancer Res Treat,2007,101(1):113-121.
|
| [16] |
Schroth W, Antoniadou L, Fritz P, et al.Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes[J].J Clin Oncol,2007,25(33):5187-5193.
|
| [17] |
Bijl MJ, van Schaik RH, Lammers LA, et al.The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users[J].Breast Cancer Res Treat,2009,118(1):125-130.
|
| [18] |
Kiyotani K, Mushiroda T, Sasa M, et al.Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy[J].Cancer Sci,2008,99(5):995-999.
|
| [19] |
Xu Y, Sun Y, Yao L, et al.Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment[J].Ann Oncol,2008,19(8):1423-1429.
|
| [20] |
Newman WG, Hadfield KD, Latif A, et al.Impaired tamoxifen metabolism reduces survival in familial breast cancer patients[J].Clin Cancer Res,2008,14(18):5913-5918.
|
| [21] |
Bonanni B, Macis D, Maisonneuve P, et al.Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial[J].J Clin Oncol,2006,24(22):3708-3709.
|
| [22] |
Bonanni B, Serrano D, Gandini S, et al.Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia[J].Clin Cancer Res,2009,15(22):7053-7060.
|
| [23] |
Wegman PP, Wingren S.CYP2D6 variants and the prediction of tamoxifen response in randomized patients: author response[J].Breast Cancer Res,2005,7(6):E7.
|
| [24] |
Nowell SA, Ahn J, Rae JM, et al.Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients[J].Breast Cancer Res Treat,2005,91(3):249-258.
|
| [25] |
Wegman P, Elingarami S, Carstensen J, et al.Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer[J].Breast Cancer Res,2007,9(1):R7.
|
| [26] |
Okishiro M, Taguchi T, Jin KS, et al.Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen[J].Cancer,2009,115(5):952-961.
|
| [27] |
Ferraldeschi R, Howell SJ, Thompson AM, et al.Avoidance of CYP2D6 inhibitors in patients receiving tamoxifen[J].J Clin Oncol,2010,28(29):e584-e585, e586.
|
| [28] |
Stearns V, Johnson MD, Rae JM, et al.Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine[J].J Natl Cancer Inst,2003,95(23):1758-1764.
|
| [29] |
Borges S, Desta Z, Li L, et al.Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism:implication for optimization of breast cancer treatment[J].Clin Pharmacol Ther,2006,80(1):61-74.
|
| [30] |
Dezentje VO, van Blijderveen NJ, Gelderblom H, et al.Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer[J].J Clin Oncol,2010,28(14):2423-2429.
|
| [31] |
Dezentje VO, Guchelaar HJ, Nortier JW, et al.Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer[J].Clin Cancer Res,2009,15(1):15-21.
|